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Abstract
During the COVID-19 pandemic, the effectiveness of the combination of hydroxychloroquine and azithromycin is
widely discussed. This treatment can cause many severe cardiac side effects that makes us discuss its utility. The aim of
this study is to describe the cardiovascular effect of hydroxychloroquine and azithromycin by analyzing surface ECG in
patients with COVID-19. This observational cohort study included Moroccan patients with COVID-19 diagnosis and
were hospitalized in Cheikh Khalifa International University Hospital, Casablanca, Morocco between March 26 and
April 20, 2020. Patients were treated with a combination of hydroxychloroquine and azithromycin over a period of at
least ten days. We were interested in the effects of this combination on the electrocardiogram. A total of 118 eligible
patients were enrolled in the study. QT interval prolongation was observed in 19% of patients under the treatment. Only
5 patients required discontinuation of treatment. The factors associated with QT prolongation are male gender (P value
0,043), age over 68 years (P value 0,09), cardiovascular comorbidity (P value 0,013), tisdale score ≥11 (P value < 0,001), and
a severe form of COVID-19 (P value < 0,001). First degree atrioventricular block was observed in 2 patients. No serious
rhythm or conduction disorders were observed in this study. QT prolongation is a real risk with the combination of
hydroxychloroquine and azithromycin. In the current context, it is necessary to select patients at high risk of severe
rhythm disturbances that require closer ECG monitoring. Treatment should be discontinued if there are alarming signs
such as QTc prolongation beyond 550 ms and the development of ventricular extrasystole or torsade de pointe.
Keywords: Hydroxychloroquine, Azithromycin, COVID-19, Electrocardiogram, QT prolongation

1. Background
he ﬁrst cases of the new coronavirus disease
2019 (COVID-19) were reported in
December 2019 and since the pandemic has
spread worldwide [1]. As of May 15, 2020, there
were four million conﬁrmed cases and 297,000
deaths worldwide [2].

T

In China, Chloroquine phosphate is the ﬁrst drug
used against COVID-19 in early clinical studies [3],
it was added to the sixth edition of the Guide for the
Interim Treatment of COVID-19 [4]. However,
based on recent studies, its effectiveness has been
claimed [5].
In Morocco, the Ministry of Health, in consultation with the scientiﬁc and technical committee of
the national program to ﬁght against coronaviruses,
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decided on 23 March 2020 to adopt the therapeutic
protocol based on hydroxychloroquine combined
with azithromycin in the various hospitals of the
kingdom. And since April 17 as prophylactic treatment in health professionals based on hydroxychloroquine [6].
This combination is currently at the heart of a vast
controversy because of its effectiveness still discussed and these potential side effects especially
cardiac [7].
Hydroxychloroquine and azithromycin are
generally well tolerated medications used in clinical
practice, but both can cause QT prolongation [8],
their wide use in this epidemic may be hazardous
especially
in
patients
with
cardiovascular
comorbidity.
The aim of this observational study is to describe
the electrical effects of the combination of hydroxychloroquine and azithromycin for the treatment of
COVID-19 by analyzing the surface ECG and to
identify high-risk patients requiring close monitoring or discontinuation of treatment.

2. Methods
2.1. Study design and participants
This observational cohort study included patients
residing in Morocco with COVID-19 diagnosis and
were hospitalized in Cheikh Khalifa International
University Hospital, Casablanca, Morocco between
March 26 and April 20, 2020.
Cheick Khalifa International University Hospital,
Mohammed VI University of Health Sciences in
Casablanca (Morocco) is one of the major authorized hospitals by government for COVID-19 patients. Our study was approved by Ethics
Committee of the Mohammed VI University of
Health Sciences in Casablanca.

351

Abbreviation
ACEI
angiotensin-converting enzyme inhibitors
AF
atrial ﬁbrillation
ARB
angiotensin receptor blockers
AVB
atrioventricular block
COVID-19
Corona Virus Infectious Disease 2019
ECG
electrocardiogram
PCI
percutaneous coronary intervention
QTm
the measured QT interval
QTc
the corrected QT interval
RT-PCR real-time reverse transcriptase polymerase chain
reaction
TdP
torsades de pointes
VES
ventricular extrasystole

30 times per minute; ﬁngertip blood oxygen saturation less than 93% at rest; partial arterial oxygen
pressure (PaO2)/fraction of inspiration oxygen
(FiO2) less than 300 mmHg. Patients with one of the
three conditions are considered as critical type:
respiratory failure, requiring mechanical ventilation; shock; multiple organ failure, requiring intensive care management.
In this work, we divided the patients in two
groups: non-severe group (mild and moderate
types) and severe group (severe and critical types).
2.3. Treatment of COVID-19
From March 26 to April 20, the hospital received
118 patients with conﬁrmed COVID-19 infection. 118
patients received the treatment established by the
Ministry of Health: combination of hydroxychloroquine at a dosage of 200 mgX2/day and azithromycin 500 mg on the ﬁrst day then 250 mgX2 per
day for 10 days. All patients had a cardiovascular
consultation with ECG prior to treatment and were
under clinical, electrical, biological monitoring.

2.2. Diagnosis and grading of COVID-19

2.4. Data collection

All consecutive patients with COVID-19
conﬁrmed by positive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) results on respiratory specimens admitted to Cheick Khalifa
International University Hospital and who were
treated with hydroxychloroquine and azithromycin
were included. Patients with contraindications to
this combination were excluded from this study.
According to the World Health Organization [1],
patients can be divided into four types as mild,
moderate, severe and critical types. Patients in severe type should meet one of the three criteria:
respiratory distress and respiratory rate higher than

The clinical data of patients were collected from
electronic medical records, including demographics,
clinical symptoms and signs, co-existing conditions,
imaging ﬁndings, laboratory results, treatment and
clinical outcomes.
A 12-lead ECG is recorded on graph paper, with a
standard calibration of the ECG signal,
1 mV ¼ 10 mm and the speed of unwinding of the
graph paper of 25 mm/s.
ECG analysis is done manually by two cardiologists who are part of this study (AE, SA). All ECG
parameters were analyzed: P-wave measurement,
PR interval, QRS, QT interval, T-wave with the
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appearance of conduction and rhythm disturbance,
and repolarization disorder.
QT intervals were measured manually from lead II
or V5 or V6 (the longest value being used) of 12-lead
ECGs from beginning of the earliest onset of the
QRS complex to the end of the T wave. The end of
the T wave was determined by extending a tangent
from steepest portion of the downslope of the T wave
until it crossed the T-P segment. During normal
sinus rhythm, QT and RR intervals were averaged
over three consecutive complexes. During atrial
ﬁbrillation, QT and RR intervals were averaged over
all complexes on the 6 s rhythm strips [9e11].
QT intervals were corrected for heart rate using
Bazett method and Fridericia: Bazett0 s formula is
used for heart rates between 60 and 85 bpm, in case
of heart rates < 60 bpm or > 85 bpm, Fridericia0 s
formula is used [10,11].
.pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Bazett0s formula: QTcBðmsÞ ¼ QTm ðmsÞ 2 RRðsÞ
.pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Fridericia0sformula:QTcFriðmsÞ¼QTmðmsÞ 3 RRðsÞ
QTm: measured QT.
The value of normal QTc is variable according to
age and gender. A normal QTc interval is < 440 ms
in prepuberty, <430 ms in post pubertal males, and
<450 ms in post pubertal females [10e12].
In patients with wide QRS(>120 ms), due to underlying intraventricular conduction defects or
paced rhythm, we use the following formula to estimate QTc interval: wide QRS adjusted QTc ¼ QTc
- (QRS duration - 100 ms) [11,12].
ECGs were recorded in all patients before drug
administration and repeated on the second, the
fourth, and the sixth day, as well as after treatment.
For patients with abnormalities, ECGs were performed at shorter intervals.
We measured the Tisdale score which is a score
the risk of QTc prolongation of drug combinations
in all patients. This score is based on clinical, biological and electrical data [13] (Table 1). If the score
is > 11/21, there is a high risk of drug-associated QT
prolongation.
2.5. Statistical analysis
After visually inspecting data, descriptive statistics
was carried out. Continuous data were expressed as
mean ± standard deviation and categorical parameters were computed as percentages, where appropriate. Based on the normality of data distribution,
Student's t-test or the ManneWhitney U test and
chi-squared test were conducted to compare

parameters between COVID-19 positive and negative individuals. Figures with p-values equal to or
less than 0.05 were considered statistically signiﬁcant. Statistical analyses were carried out by means
of the commercial software “Statistical Package for
Social Sciences” (SPSS for Windows, version 24.0,
IBM Corp., Armonk, NY, USA).

3. Results
3.1. Demographic and clinical characteristic
Our cohort included 52 female patients (44%), and
66 male patients (55,9%). The average age was 46
years, with 10 patients under 18 years of age, and
extremes from 6 years to 86 years.
75 (63%) patients had no particular medical history, 33 (27,9%) patients were hypertensive, 17
(14,4%) patients were diabetic, 8 (6,7%) patients had
ischemic heart disease. Three patients had atrial
ﬁbrillation (AF): one patient had permanent AF on
beta blocker and anticoagulation and two patients
had paroxysmal AF on an antiarrhythmic drug
(ﬂecainide) and on anticoagulation (Table 2).
According to the clinical presentation of COVID19 infection, 79 (66%) patients had a non-severe
form and 39 (33%) patients had a severe form,
requiring hospitalization in an intensive care unit.
55 (46%) patients were completely asymptomatic,
and 24 (20%) patients complained of moderate
symptoms like agnosia and anosmia. 41 (34%) patients had fever and 39 (33%) patients had a dry
cough. No direct cardiac damage related to COVID19 was reported in our study.
3.2. Electrocardiogram
We analyzed and compared the ECG performed
before and after the initiation of treatment (after 2, 4
and 6 days).
Table 1. Risk Score For Drug-Associated QTc Prolongation: The Tisdale
score [13].  6 predicts low risk, 7e10 medium risk, and 11 high risk
of drug-associated QT prolongation.
Risk Factors

Points

Age 68 y
Female sex
Loop diuretic
Serum Kþ 3.5 mEq/L
Admission QTc 450 ms
Acute MI
If one QTc-prolonging drug
If  2 QTc-prolonging drugs
Sepsis
Heart failure

1
1
1
2
2
2
3
6
3
3

Maximum Risk Score

21

Table 2. Baseline characteristics of the 118 patients.

Table 3. ECG parameter variability before and after treatment.

VARIABLE

TOTAL

Female
Male
Age, mean
Cardiovascular Risk Factors
Hypertension
Diabetes type I/II
Smoking
Dyslipidemia
Overweight
Known cardiovascular disease
Ischemic heart disease
Coronary bypass surgery
Valvulopathy
Congestive heart failure
atrial ﬁbrillation
Non-Cardiovascular Medical History
Asthma/Allergy
Hyper or hypothyroidism
Depression/anxiety
Kidney failure
Neoplasm
Vascular cerebral accident
Alcohol
Drug therapy
beta-blockers
ACEI/ARB
calcium Inhibitor
statin
ﬂecainide
amiodarone
Diuretic
Platelet antiaggregant
Antidepressant
Sedative/hypnotics/anxiolytic/anti-psychotics
Salbutamol
COVID-related symptoms
Cough
Fever
Asthenia
Headache
Digestive signs: diarrheal, vomiting
Anosmia
Agnosia
Chest pain
Dyspnea
Palpitation
Unconsciousness
Asymptomatic
COVID-19 severity
Non-severe group
Patient admitted on reanimation
Death

52 (44,06%)
66 (55,93%)
46 years
33
17
15
30
12

(27,96%)
(14,40%)
(12,71%)
(25,42%)
(10,16%)

8
1
4
1
3

(6,77%)
(0,84%)
(3,38%)
(0, 84%)
(2,54%)

8
4
4
1
2
2
2

(6,77%)
(3,38%)
(3,38%)
(0,84%)
(1,69%)
(1,69%)
(1,69%)

8 (6,77%)
28 (23,72%)
14 (11,86%)
12 (10,16%)
2 (1,69%)
1 (0,84%)
6 (5,06%)
15 (12,71%)
3 (2,54%)
2 (1,69%)
7 (5,93%)
39 (33,05%)
41 (34,74%)
13 (11,01%)
6 (5,08%)
7 (5,93%)
14 (11,86%)
16 (13,55%)
22 (18,64%)
22 (18,64%)
11 (9,32%)
0 (0%)
20 (16,94%)
79 (66,94%)
39 (33,05%)
9 (7,62%)

The results are presented in the Table 3.
a. The PR interval

Two patients presented with an extension of the
PR interval. No atrioventricular conduction disorder
was found.

P wave (ms)
PR (ms)
QRS duration (ms)
Corrected QT (ms)
T wave (ms)

ECG before
treatmenta

ECG after
treatmenta

p-valueb

82,25 ± 15,7
150,11 ± 26,3
85,72 ± 17,2
427,33 ± 39,2
427,33 ± 39,2

84,59 ± 15,2
153,64 ± 28,9
88,53 ± 18,4
443,70 ± 44,4
443,70 ± 44,4

0,091
0,036
0,013
<104
<104

Data indicated as mean ± SD.
Paired samples t-tests for within-group comparisons of ECG
changes before and after treatment.
a

b

b. The QT interval

The prolonged corrected QT is deﬁned as >460 ms
in prepuberty, > 450 ms in post pubertal males and
>470 ms in post pubertal females [12].
After hydroxychloroquine and azithromycin
combination treatment, 23 (19,49%) patients experienced QT prolongation. 18 patients (15.2%)
increased their QTc by more than 40 ms (Fig. 1). QT
prolongation occurs more in men, and in patients
over 68 years of age. Hypokalemia was presented in
only one patient with QTc prolongation.
In patients with prolonged QTc, Cardiovascular
comorbidity (hypertension, diabetic, heart diseases)
was present in 34%, the Tisdale score was  to 7 in
all patients. It was 11 in 5 patients.
69.5% of patients with QT prolongation were in
severe COVID-19 infection, 4 of whom died as a
result of the infection. The characteristics of patients
with QTc prolongation are presented in Table 4.
The mean time to onset of these electrical signs
was 2 days after the start of treatment.
Treatment was discontinued in 5 patients who had
a prolonged QTc beyond 550 ms, with the appearance of ventricular extrasystole (VES) in two of
them. No torsades de pointes (TdP) or severe
rhythm disorders occurred.
c. Rhythm disorder

Four patients had ventricular extrasystole: Two
patients had left delayed monomorphic VES
without QTc prolongation, both patients are being
followed for ischemic heart disease under
treatment.
The other two patients had isolated monomorphic
VES without bigeminism or trigeminism, their QTc
increased from 525 ms to 546 ms for the ﬁrst patient,
and from 508 ms to 560 ms for the second patient,
there was no dyskalemia. The combination of
hydroxychloroquine and azithromycin was stopped.
A patient who had a paroxysmal AF under ﬂecainide and anticoagulant was admitted initially in
sinus rhythm. He had a long QT (540 ms) on the
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650

600

QTc interval, ms

550
500
450
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350
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250

Baseline Qtc

QTc aer treatment

Fig. 1. Individual changes in corrected QT (QTc) interval.

second day of with recurrence AF despite being on
ﬂecainide. The combination of hydroxychloroquine
and azithromycin was stopped. The patient
returned to a sinus rhythm and to a normal QT
space.
A patient with permanent AF on betablocker and
anticoagulant therapy had a reduction in AF and
returned to sinus rhythm without QT prolongation.
d. Repolarization disorder:

T-wave elongation was observed in 30%. U wave
exaggeration was observed in 19% of patients.
e. Morphological abnormality

P-wave elongation was observed in 5%.
No electrical signs of left ventricular hypertrophy
were observed after treatment. (Cornell and Sokolow indexes increased by 1%)

The heart axis hasn't changed.

4. Discussion
Hydroxychloroquine have a long-standing history
in the prevention and treatment of malaria and the
treatment of chronic inﬂammatory diseases
including systemic lupus erythematosus and rheumatoid arthritis. And for its antiviral action, it is
used in the treatment of COVID-19 [14,15].
The toxic effects of hydroxychloroquine are well
detailed and described in the literature. Cardiac
toxicity of hydroxychloroquine is uncommon, it can
be either a rhythm disorder with prolonged QTc
and risk of sudden death, or conduction disorder, or
cardiomyopathy. These toxic effects depend on the
duration of exposure and cumulative dose, so there
may be acute toxicity from high doses or toxicity
from chronic exposure [16].

Table 4. Characteristics of patients with QTc prolongation.
Gender:
Female
Male
Age> 68
kalemia
hypokalemia
hyperkalemia
Cardiovascular comorbidity
Tisdale risk score
6
Between 7 and 10
11
Initial QTc 500 ms
Severe form of COVID-19

QTc normal (n ¼ 95)

Prolonged QTc (n ¼ 23)

47 (49,47%)
48 (50,52%)
11 (11,57%)

6 (26,08%)
17 (73,91%)
7 (30,43%)

2 (2,10%)
3 (3,15%)
7 (7,36%)

1 (4,34%)
1 (4,34%)
8 (34,78%)

77 (81,05%)
16 (16,84%)
2 (2,10%)
1 (1,05%)
17 (17,89%)

9 (39,13%)
9 (39,13%)
5 (21,73%)
5 (21,73%)
16 (69,56%)

P value
0,043

0,014
0,82

0,013
<0,001

<0,001
<0,001

In the context of COVID-19, the wide prescription
of hydroxychloroquine is not safe: hydroxychloroquine is prescribed at high doses for a
shortened duration in combination with azithromycin, also known for its proarrhythmic properties, and this in patients who may have
comorbidities, or a severe infectious form [17].
QTc prolongation du to hydroxychloroquine are
the consequence of the quinidine-like membrane
stabilizing action, type IA according to the Vaughan
and Williams classiﬁcation. It is mainly due to the
blocking of the sodium channels of the cardiac cell
[18].
QT prolongation was observed in 19% of patients,
which is slightly higher to what has been reported in
patients with COVID-19 receiving hydroxychloroquine in a U.S. study (11.0%) or a Brazilian
study (15%) [19,20].
QTc prolongation is dose-dependent, Borba et al.
conducted clinical trial testing two doses of chloroquine in patients with COVID-19. They planned to
include 440 patients but stopped after 81 patients
were enrolled due to excessive QTc prolongation
and a higher mortality in the high-dose group (patients receiving 1200 mg daily for 10 days) compared
to the low-dose group (in which patients received
450 mg daily for 4 days after an initial dose of
900 mg on the ﬁrst day) [20]. QTc prolongation was
observed in 11% of patients on low dose, and in
18.9% of patients on high dose. However, in this
study they used chloroquine diphosphate which is
more toxic than hydroxychloroquine, and patients
received in addition to chloroquine diphosphate,
azithromycin, ceftriaxone, and Oseltamivir who also
have been implicated in QTc prolongation and
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proarrhythmic events. The COVID-19 forms were
more severe.
In our study, severe and critical forms of COVID19 are less frequent, with a slightly lower mortality
rate.
The factors associated with QTc prolongation
were: age >68 years, male gender, cardiovascular
comorbidity, Tisdale score 11, and a severe form of
COVID-19.
QTc prolongation is more frequent in men (odds
ratio 2.8; P value 0,043), it is similar to what has been
described in Chorin study [19]. In the clinical trial by
Borda et al. [20], frequency was similar between
men and women. Apart from COVID-19, Tisdale
reported a more frequent risk of QTc prolongation
in women [13].
Age over 68 years is a factor associated with QTc
prolongation as reported in several studies (P value
0,014). Cardiotoxicity may be enhanced by older
age, pre-existing cardiac disease and renal
insufﬁciency.
In our series, diabetes alone is not a predisposing
factor for QTc prolongation. However, the combination of comorbidities such as hypertension, diabetes, heart diseases and kidney failure are
predisposing factors. Conversion enzyme inhibitors
and calcium channel blockers have not shown a
causal relationship with electrical abnormalities.
Dyskalemia is not a predisposing factor for QTc
prolongation in our study unlike what was reported
by Tisdale et al. [13].
A severe COVID-19 infection form is associated
with a high risk of QTc prolongation, which may be
explained by sepsis with multivisceral failure. This
has been reported in several studies [13,20].

Fig. 2. Protocol proposing for electrical monitoring of patients with COVID-19. QTc: corrected QT, VES: ventricular extrasystole, TdP: torsades de
pointes.
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In the context of COVID-19, the addition of azithromycin to hydroxychloroquine is associated with
greater QTc prolongation according to recently
published studies [21,22].
QTc interval prolongation can be considered as a
prognostic criterion for the inherent severity of
COVID-19 infection, in addition to the need to discontinue ﬁrst-line therapy [21].
Other electrical abnormalities described in the
literature as severe conduction disorders have not
been reported in our series [23]. We observed
moderate P-wave elongation and QRS widening,
and it is similar to what has been described in the
long-term use of the treatment [24].
The Moroccan and American Society of Cardiology recommendation focus on baseline risk assessment, frequent QTc monitoring, and strict cutoffs
for therapy cessation [6, 25].
Finally, the introduction of combined hydroxychloroquine and azithromycin therapy requires a
rigorous follow-up of the patients, we propose the
following protocol for monitoring patients with
COVID-19 (Fig. 2).

5. Conclusions
The combination of hydroxychloroquine and azithromycin is not safe in the context of COVID-19. QTc
prolongation is a real risk. Therefore, it is necessary to
identify high-risk rhythmic patients in whom ECG
monitoring should be performed very closely. Treatment should be discontinued if there are any alarming
signs: QTc> 550 ms or appearance of VES, or TdP.

6. Limits
The main limitation of the study is the limited
number of patients included. Viral cardiac involvement was not completely ruled out in all patients,
extensive cardiac workup was performed only in
symptomatic patients.
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